Michal Sarfaty

ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 7

Top Venues

Cancers

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Clinical cancer research : an official journal of the American Association for Cancer Research

Cancer medicine

Memorial Sloan Kettering Cancer Center

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Memorial Sloan Kettering Cancer Center Aug 01 2019

United States

Fellow :: Gme-medicine

Publications

Brendan J Guercio, Michal Sarfaty, Min Yuen Teo, Neha Ratna, Cihan Duzgol, Samuel A Funt, Chung-Han Lee, David Henry Aggen, Ashley M Regazzi, Zhiyu Chen, Michael Lattanzi, Hikmat A Al-Ahmadie, Angela Rose Brannon, Ronak H Shah, Carissa E Chu, Andrew T Lenis, Eugene J Pietzak, Bernard H Bochner, Michael F Berger, David B Solit, Jonathan E Rosenberg, Dean F Bajorin, Gopakumar V Iyer
Clinical and genomic landscape of FGFR3-altered urothelial carcinoma and treatment outcomes with erdafitinib: a real-world experience. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Michal Sarfaty, Mahdi Golkaram, Samuel A Funt, Hikmat A Al-Ahmadie, Shannon Kaplan, Fan Song, Ashley M Regazzi, Vladimir Makarov, Fengshen Kuo, Irina Ostrovnaya, Venkatraman Seshan, Chen Zhao, Benjamin Greenbaum, Li Liu, Jonathan E Rosenberg, Timothy A Chan
Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Shira Sagie, Michal Sarfaty, Meital Levartovsky, Hadas Gantz Sorotsky, Raanan Berger, Ruth Percik, Moran Gadot
RCC Real-World Data: Prognostic Factors and Risk Stratification in the Immunotherapy Era. Cancers 14 (13) (2022)
Shira Sagie, Moran Gadot, Meital Levartovsky, Hadas Gantz Sorotsky, Raanan Berger, Michal Sarfaty, Ruth Percik
Immune-Related Thyroiditis as a Predictor for Survival in Metastatic Renal Cell Carcinoma. Cancers 14 (4) (2022)
Michal Sarfaty, Assaf Moore, Ashley M Regazzi, Aaron P Mitchell, Jonathan E Rosenberg
The Cost of Enfortumab Vedotin Wastage Due to Vial Size-A Real-World Analysis. Cancers 13 (23) (2021)
Michal Sarfaty, Karissa A Whiting, Min Yuen Teo, Chung-Han Lee, Vanessa Peters, Jennifer Durocher, Ashley M Regazzi, Asia S McCoy, Grace Hettich, Achim A Jungbluth, Hikmat A Al-Ahmadie, Irina Ostrovnaya, Joshua Chaim, Dean F Bajorin, Jonathan E Rosenberg, Gopakumar V Iyer, Samuel A Funt
A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tract. Cancer medicine 10 (3) (2020)
Daniel Reinhorn, Michal Sarfaty, Moshe Leshno, Assaf Moore, Victoria Neiman, Eli Rosenbaum, Daniel A Goldstein
A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma. The oncologist 24 (3) (2019)

Michal Sarfaty.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Michal Sarfaty